{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:23:21Z","timestamp":1715991801470},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1245\/s10434-020-09114-0","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T15:10:28Z","timestamp":1599750628000},"page":"4870-4871","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Melanomas of Unknown Primary May Have a Distinct Molecular Classification to Explain Differences in Patient Outcomes"],"prefix":"10.1245","volume":"27","author":[{"given":"Georgia M.","family":"Beasley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"9114_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2014.09.029","volume":"72","author":"JM Bae","year":"2015","unstructured":"Bae JM, Choi YY, Kim DS, et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2015;72:59\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"9114_CR2","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1200\/JCO.2008.18.9845","volume":"27","author":"CC Lee","year":"2009","unstructured":"Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009;27:3489\u201395.","journal-title":"J Clin Oncol"},{"key":"9114_CR3","doi-asserted-by":"publisher","first-page":"e1677139","DOI":"10.1080\/2162402X.2019.1677139","volume":"8","author":"T Gambichler","year":"2019","unstructured":"Gambichler T, Chatzipantazi M, Schr\u00f6ter U, Stockfleth E, Gedik C. Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. Oncoimmunology. 2019;8:e1677139.","journal-title":"Oncoimmunology"},{"key":"9114_CR4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09112-2","author":"JP De Andrade","year":"2020","unstructured":"De Andrade JP, Wong P, O\u2019Leary MP, et al. Multidisciplinary care for melanoma of unknown primary: Experience in the era of molecular profiling. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-09112-2.","journal-title":"Ann Surg Oncol"},{"key":"9114_CR5","doi-asserted-by":"crossref","unstructured":"Pires da Silva I, Wang KYX, Wilmott JS, et al. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. Clin Cancer Res. 2019;25:1272\u20139.","DOI":"10.1158\/1078-0432.CCR-18-1680"},{"key":"9114_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959\u201361.","journal-title":"Science."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09114-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09114-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09114-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T01:35:45Z","timestamp":1631237745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09114-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":6,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9114"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09114-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Georgia M. Beasley served on the advisory board of Regeneron in 2020.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}